Financial PerformanceLifeward reported $6.1M in revenue for 3Q24, representing a 39% YoY growth from $4.4M in 3Q23.
Market OpportunityThe market for personal exoskeletons amongst Medicare Part B patients is sufficiently large for Lifeward to be a profitable company.
Product DevelopmentThe company expects to launch a new personal exoskeleton model, ReWalk 7 by YE24, pending FDA approval.